Jakafi 20 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FCYH6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,677
Award facts
- Contract value 100% obligated
- $24,676.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $24.7K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of JAKAFI (ruxolitinib) 20 mg tablets in quantities of 60 units. The award was issued on December 15, 2025, with an ultimate completion date of December 16, 2025, and represents a non-set-aside procurement. This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9M single-award contract established on November 13, 2025, designed to support Department of Defense pharmaceutical supply requirements through December 31, 2036.
DMS Pharmaceutical Group, registered in the System for Award Management since 2001, serves as a critical supplier within the federal pharmaceutical supply chain and has demonstrated substantial contracting activity with the Defense Logistics Agency's Medical Supply Chain division. The broader PPV-G GEN V acquisition strategy, valued at $30.3 billion government-wide, establishes multiple regional prime vendor contractors to deliver comprehensive pharmaceutical products including branded and generic prescription medications, biologics, vaccines, and medical consumables to military healthcare facilities worldwide. No subcontractors are identified for this delivery order, and the firm fixed-price structure ensures cost predictability for this pharmaceutical supply transaction supporting Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FCYH6?
SPE2DR26FCYH6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FCYH6 worth?
The government has obligated $24,677 on SPE2DR26FCYH6.
Is contract SPE2DR26FCYH6 an order under another contract?
Yes. SPE2DR26FCYH6 is a delivery order under SPE2DR25D9153, an indefinite delivery contract.
Was contract SPE2DR26FCYH6 competed?
The extent of competition for SPE2DR26FCYH6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award